Acute bacterial skin and skin-structure infection Market: Epidemiology, Therapies, Companies, DelveInsight | MicuRx, Basilea pharmaceuticals, AbbVie, Cubist Pharms LLC, Nabriva Therapeutics, Melinta Therapeutics, Durata Therapeutics

Acute bacterial skin and skin-structure infection therapies, such as DALVANCE (dalbavancin), ORBACTIV, MRX-4, ZEVTERA (ceftobiprole), and others, are expected to boost the Acute bacterial skin and skin-structure infection Market in the upcoming years.

DelveInsight has launched a new report on "Acute bacterial skin and skin-structure infection - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Acute bacterial skin and skin-structure infection, historical and forecasted epidemiology as well as the Acute bacterial skin and skin-structure infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Acute bacterial skin and skin-structure infection market report @ https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Acute bacterial skin and skin-structure infection Market Report:

In April 2024, the U.S. Food and Drug Administration (FDA) approved Zevtera (ceftobiprole medocaril sodium), a broad-spectrum cephalosporin antibiotic, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. This approval provides healthcare providers with an additional option to address serious skin infections caused by various bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) .
Zevtera was granted priority review, fast track, and qualified infectious disease product designations by the FDA, reflecting its potential to meet an unmet medical need in treating ABSSSI . The approval was based on data from four randomized controlled trials demonstrating Zevtera's efficacy in treating ABSSSI. In these studies, 91.3% of patients receiving Zevtera achieved an early clinical response (48 to 72 hours after starting treatment), compared to 88.1% in the comparator group .
In July 2021, the US Food and Drug Administration (FDA) approved AbbVie's DALVANCE (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients, including those from birth.
The highest rate of MRSA hospitalizations occurred among the elderly, with 360.8 MRSA-related stays per 100,000 patients over 65 years of age, more than three times higher than any other age group. The rates for other age groups were 114.7 stays for infants, 19.2 for children aged 1 to 17, 58.1 for adults aged 18 to 44, and 111.5 for those aged 45 to 64 per 100,000.
According to secondary analysis, ABSSSI accounted for nearly 870,000 hospital admissions in the United States in 2004, reflecting a nearly 30% increase in incidence over a 4-year period. Among almost 5 million adult ABSSSI hospital admissions, there was a 17.3% increase from 2005 to 2011. ABSSSI patients were predominantly male (50.8%), white (60.3%), with a mean age of 55.7 years.
The dynamics of the ABSSSI market are anticipated to change with the arrival of new treatment options, adjustments in regulatory policies, and shifts in healthcare spending priorities. These factors could result in heightened competition among pharmaceutical companies and improved patient outcomes.
Key Acute bacterial skin and skin-structure infection companies such as DALVANCE (dalbavancin), ORBACTIV, MRX-4, ZEVTERA (ceftobiprole), and others are evaluating new drugs for Acute bacterial skin and skin-structure infection to improve the treatment landscape.
Promising Acute bacterial skin and skin-structure infection therapies include DALVANCE (dalbavancin), ORBACTIV, MRX-4, ZEVTERA (ceftobiprole), and others.

Acute bacterial skin and skin-structure infection Overview

Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) encompasses a wide range of infections affecting the skin and underlying soft tissues, usually caused by bacteria. These infections can vary in severity, with symptoms including localized inflammation, redness, warmth, and occasionally pus. Common bacteria responsible for ABSSSI include Staphylococcus aureus (including methicillin-resistant strains, MRSA), Streptococcus pyogenes, and other Gram-positive and Gram-negative bacteria.

Acute bacterial skin and skin-structure infection Market Outlook

The treatment of ABSSSI focuses on alleviating symptoms, improving quality of life, stopping disease progression, and preventing recurrence. Initial treatment often involves oral antibiotics targeting streptococci, particularly for cellulitis. However, the rise of MRSA has prompted a reassessment of treatment approaches. For mild non-purulent infections, common antibiotics include penicillin, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, and clindamycin.

For MRSA infections, both oral and intravenous treatments are available, including drugs like sulfamethoxazole-trimethoprim, clindamycin, minocycline, doxycycline, vancomycin, daptomycin, linezolid, ceftaroline, and telavancin. MRSA-targeting antibiotics are especially needed when the infection is linked to penetrating trauma, such as from IV drug use. The choice and duration of treatment depend on infection severity, patient factors, and antibiotic resistance.

Newer antibiotics such as DALVANCE, ORBACTIV, and SIVEXTRO have emerged to combat MRSA, offering long half-lives that enable less frequent dosing, improving patient compliance. Oritavancin, a lipoglycopeptide with a unique mechanism of action, also presents a promising option. Its long half-life allows single-dose administration, simplifying treatment and potentially improving adherence, while its broad spectrum, including MRSA, makes it a valuable tool in ABSSSI management.

Ongoing research continues to drive progress in finding more effective treatments for ABSSSI, with the potential for improved patient outcomes and reduced healthcare burdens. DelveInsight predicts significant changes in the ABSSSI market from 2020 to 2034.

Discover how the Acute bacterial skin and skin-structure infection market is rising in the coming years @ https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Bacterial Skin and Skin-Structure Infection Marketed Drugs
DALVANCE (dalbavancin) : ABBVIE /Durata Therapeutics
ORBACTIV: Melinta Therapeutics

Acute bacterial skin and skin-structure infection Emerging Drugs
MRX-4: MicuRx
ZEVTERA (ceftobiprole): Basilea Pharmaceutica

Scope of the Acute bacterial skin and skin-structure infection Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute bacterial skin and skin-structure infection Companies: MicuRx, Basilea pharmaceuticals, AbbVie, Cubist Pharms LLC, Nabriva Therapeutics, Melinta Therapeutics, Durata Therapeutics, and others
Key Acute bacterial skin and skin-structure infection Therapies: DALVANCE (dalbavancin), ORBACTIV, MRX-4, ZEVTERA (ceftobiprole), and others
Acute bacterial skin and skin-structure infection Therapeutic Assessment: Acute bacterial skin and skin-structure infection current marketed and Acute bacterial skin and skin-structure infection emerging therapies
Acute bacterial skin and skin-structure infection Market Dynamics: Acute bacterial skin and skin-structure infection market drivers and Acute bacterial skin and skin-structure infection market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Acute bacterial skin and skin-structure infection Unmet Needs, KOL's views, Analyst's views, Acute bacterial skin and skin-structure infection Market Access and Reimbursement

To know what's more in our Acute bacterial skin and skin-structure infection report, visit https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Acute bacterial skin and skin-structure infection Market Report:
Acute bacterial skin and skin-structure infection market report covers a descriptive overview and comprehensive insight of the Acute bacterial skin and skin-structure infection Epidemiology and Acute bacterial skin and skin-structure infection market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Acute bacterial skin and skin-structure infection market report provides insights into the current and emerging therapies.
The Acute bacterial skin and skin-structure infection market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Acute bacterial skin and skin-structure infection market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute bacterial skin and skin-structure infection market.

Got queries? Click here to know more about the Acute bacterial skin and skin-structure infection market Landscape https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Acute bacterial skin and skin-structure infection Patient Share (%) Overview at a Glance
5. Acute bacterial skin and skin-structure infection Market Overview at a Glance
6. Acute bacterial skin and skin-structure infection Disease Background and Overview
7. Acute bacterial skin and skin-structure infection Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute bacterial skin and skin-structure infection
9. Acute bacterial skin and skin-structure infection Current Treatment and Medical Practices
10. Unmet Needs
11. Acute bacterial skin and skin-structure infection Emerging Therapies
12. Acute bacterial skin and skin-structure infection Market Outlook
13. Country-Wise Acute bacterial skin and skin-structure infection Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Acute bacterial skin and skin-structure infection Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Acute bacterial skin and skin-structure infection Market Outlook 2034 https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Acute bacterial skin and skin-structure infection Pipeline Insights, DelveInsight

"Acute bacterial skin and skin-structure infection Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute bacterial skin and skin-structure infection market. A detailed picture of the Acute bacterial skin and skin-structure infection pipeline landscape is provided, which includes the disease overview and Acute bacterial skin and skin-structure infection treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.